Development of the ESEx index: a tool for predicting risk of recurrent severe COPD exacerbations

被引:0
|
作者
Valera-Novella, Elisa [4 ,5 ]
Bernabeu-Mora, Roberto [1 ,2 ,3 ]
Montilla-Herrador, Joaquina [4 ,5 ]
Escolar-Reina, Pilar [4 ,5 ]
Garcia-Vidal, Jose Antonio [5 ,6 ]
Medina-Mirapeix, Francesc [4 ,5 ]
机构
[1] Hosp Gen Univ Morales Meseguer, Dept Pneumol, Adva Marques Velez S-N, Murcia 30008, Spain
[2] Univ Murcia, Dept Internal Med, Murcia, Spain
[3] Inst Murciano Invest Biosanitaria IMIB, Res Grp Fisioterapia & Discapacidad, Murcia, Spain
[4] Univ Murcia, Dept Phys Therapy, Murcia, Spain
[5] Inst Murciano Invest Biosanitaria Virgen Arrixaca, Res Grp Fisioterapia & Discapacidad, Murcia, Spain
[6] Univ Murcia, Murcia, Spain
关键词
COPD; five-repetition sit-to-stand test (5-STS); hospital admission; recurrent exacerbation; 6-minute-walk test (6MWT); OBSTRUCTIVE PULMONARY-DISEASE; HOSPITALIZATION;
D O I
10.1177/20406223231155115
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background:In chronic obstructive pulmonary disease (COPD), multiple recurrent severe exacerbations that require hospitalization can occur. These events are strongly associated with death and other clinical complications. Objectives:We aimed to develop a prognostic model that could identify patients with COPD that are at risk of multiple recurrent severe exacerbations within 3 years. Design:Prospective cohort. Methods:The derivation cohort comprised patients with stable, moderate-to-severe COPD. Multivariable logistic regression analyses were performed to develop the final model. Based on regression coefficients, a simplified index (ESEx) was established. Both, model and index, were assessed for predictive performance by measuring discrimination and calibration. Results:Over 3 years, 16.4% of patients with COPD experienced at least three severe recurrent exacerbations. The prognostic model showed good discrimination of high-risk patients, based on three characteristics: the number of severe exacerbations in the previous year, performance in the five-repetition sit-to-stand test, and in the 6-minute-walk test. The ESEx index provided good level of discrimination [areas under the receiver operating characteristic curve (AUCs): 0.913]. Conclusions:The ESEx index showed good internal validation for the identification of patients at risk of three recurrent severe COPD exacerbations within 3 years. These tools could be used to identify patients who require early interventions and motivate patients to improve physical performance to prevent recurrent exacerbations.
引用
收藏
页数:11
相关论文
共 34 条
  • [21] Development and validation of a prediction score to assess the risk of incurring in COPD-related exacerbations: a population-based study in primary care
    Lapi, Francesco
    Marconi, Ettore
    Lombardo, Francesco Paolo
    Cricelli, Iacopo
    Ansaldo, Elena
    Gorini, Marco
    Micheletto, Claudio
    Di Marco, Fabiano
    Cricelli, Claudio
    RESPIRATORY MEDICINE, 2024, 227
  • [22] Predicting risk of undiagnosed COPD in primary care: Development and validation of the TargetCOPD model
    Haroon, Shamil
    Adab, Peymane
    Riley, Richard
    Fitzmaurice, David
    Jordan, Rachel
    Dickens, Andy
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [23] QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study
    Wedzicha, Jadwiga A.
    Decramer, Marc
    Olsson, Petter
    Chen, Hungta
    Fogel, Robert
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [24] Impact of age-related comorbidities on the risk of COPD exacerbations in subjects with severe airflow limitation: A pan-European study
    Burgel, Pierre-Regis
    Paillasseur, Jean-Louis
    Partridge, Martin
    Miravitlles, Marc
    Cazzola, Mario
    Vogelmeier, Claus
    Leynaud, Delphine
    Ostinelli, Juliette
    Kessler, Romain
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [25] The impact on severe exacerbations of establishing a cross-sectorial lung team for patients with COPD at high risk of exacerbating: a pilot study
    Iversen, Birgit Refsgaard
    Rodkjaer, Lotte orneborg
    Bregnballe, Vibeke
    Lokke, Anders
    EUROPEAN CLINICAL RESPIRATORY JOURNAL, 2021, 8 (01):
  • [26] Development and validation of a novel AI-derived index for predicting COPD medical costs in clinical practice
    Liu, Guan-Heng
    Li, Chin-Ling
    Yang, Chih-Yuan
    Liu, Shih-Feng
    COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2025, 27 : 541 - 547
  • [27] Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD
    Lai, Chih-Cheng
    Wang, Ya-Hui
    Wang, Cheng-Yi
    Wang, Hao-Chien
    Yu, Chong-Jen
    Chen, Likwang
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018, 13 : 867 - 874
  • [28] Natural history and risk stratification of patients undergoing non-invasive ventilation in a non-ICU setting for severe COPD exacerbations
    Sainaghi, Pier Paolo
    Colombo, Davide
    Re, Azzurra
    Bellan, Mattia
    Sola, Daniele
    Balbo, Piero Emilio
    Campanini, Mauro
    Della Corte, Francesco
    Navalesi, Paolo
    Pirisi, Mario
    INTERNAL AND EMERGENCY MEDICINE, 2016, 11 (07) : 969 - 975
  • [29] Predicting the risk of severe COVID-19 outcomes in primary care: development and validation of a vulnerability index for equitable allocation of effective vaccines
    Lapi, Francesco
    Domnich, Alexander
    Marconi, Ettore
    Rossi, Alessandro
    Grattagliano, Ignazio
    Lagolio, Erik
    Medea, Gerardo
    Sessa, Aurelio
    Cricelli, Iacopo
    Icardi, Giancarlo
    Cricelli, Claudio
    EXPERT REVIEW OF VACCINES, 2022, 21 (03) : 377 - 384
  • [30] Utility of the combination of serum highly-sensitive C-reactive protein level at discharge and a risk index in predicting readmission for acute exacerbation of COPD
    Chang, Chun
    Zhu, Hong
    Shen, Ning
    Han, Xiang
    Chen, Yahong
    He, Bei
    JORNAL BRASILEIRO DE PNEUMOLOGIA, 2014, 40 (05) : 495 - 503